News

MELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City.

Peer-reviewed publication of ProstACT SELECT 1 results confirm the utility of 68 Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach 2. Consistent with previously reported results 3, the publication highlights TLX591-Tx’s clinical differentiation and

First patient dosed in Phase 3 LUTEON 1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). LUTEON is the first Phase 3 study of a CAIX 2 -targeted radiopharmaceutical therapy in ccRCC. MELBOURNE (Australia) and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE)

First patients dosed in OPTIMAL-e 1 Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent’s Hospital Sydney. OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the OPTIMAL-PSMA 2 study which recently completed